{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:06:06Z","timestamp":1793743566487,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Protein J"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10930-023-10114-8","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:03:03Z","timestamp":1682326983000},"page":"343-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors"],"prefix":"10.1007","volume":"42","author":[{"given":"Amrutha M","family":"C","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silja","family":"Wessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthe","family":"Ponnuraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"10114_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5483\/bmbrep.2005.38.3.266","volume":"38","author":"YK Dong","year":"2005","unstructured":"Dong YK, Kyeong KK (2005) Structure and function of HtrA family proteins, the key players in protein quality control. J Biochem Mol Biol 38:266\u2013274. https:\/\/doi.org\/10.5483\/bmbrep.2005.38.3.266","journal-title":"J Biochem Mol Biol"},{"key":"10114_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00018-012-1076-4","volume":"70","author":"G Hansen","year":"2013","unstructured":"Hansen G, Hilgenfeld R (2013) Architecture and regulation of HtrA-family proteins involved in protein quality control and stress response. Cell Mol Life Sci 70:761\u2013775. https:\/\/doi.org\/10.1007\/s00018-012-1076-4","journal-title":"Cell Mol Life Sci"},{"key":"10114_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-019-1633-1","volume":"19","author":"CM Abfalter","year":"2019","unstructured":"Abfalter CM, Bernegger S, Jarzab M et al (2019) The proteolytic activity of Listeria monocytogenes HtrA. BMC Microbiol 19:1\u20139. https:\/\/doi.org\/10.1186\/s12866-019-1633-1","journal-title":"BMC Microbiol"},{"key":"10114_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-4749-4-3","volume":"4","author":"M Boehm","year":"2012","unstructured":"Boehm M, Hoy B, Rohde M et al (2012) Rapid paracellular transmigration of Campylobacter jejuni across polarized epithelial cells without affecting TER: role of proteolytic-active HtrA cleaving E-cadherin but not fibronectin. Gut Pathog 4:1\u201312. https:\/\/doi.org\/10.1186\/1757-4749-4-3","journal-title":"Gut Pathog"},{"key":"10114_CR5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/embor.2010.114","volume":"11","author":"B Hoy","year":"2010","unstructured":"Hoy B, L\u00f6wer M, Weydig C et al (2010) Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. EMBO Rep 11:798\u2013804. https:\/\/doi.org\/10.1038\/embor.2010.114","journal-title":"EMBO Rep"},{"key":"10114_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1128\/IAI.73.1.563-572.2005","volume":"73","author":"C Rigoulay","year":"2005","unstructured":"Rigoulay C, Entenza JM, Halpern D et al (2005) Comparative analysis of the roles of HtrA-like surface proteases in two virulent Staphylococcus aureus strains. Infect Immun 73:563\u2013572. https:\/\/doi.org\/10.1128\/IAI.73.1.563-572.2005","journal-title":"Infect Immun"},{"key":"10114_CR7","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1128\/IAI.72.6.3584-3591.2004","volume":"72","author":"YM Ibrahim","year":"2004","unstructured":"Ibrahim YM, Kerr AR, McCluskey J, Mitchell TJ (2004) Role of HtrA in the virulence and competence of Streptococcus pneumoniae. Infect Immun 72:3584\u20133591. https:\/\/doi.org\/10.1128\/IAI.72.6.3584-3591.2004","journal-title":"Infect Immun"},{"key":"10114_CR8","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1021\/bi701929m","volume":"47","author":"NN MohamedMohaideen","year":"2008","unstructured":"MohamedMohaideen NN, Palaninathan SK, Morin PM et al (2008) Structure and function of the virulence-associated high-temperature requirement A of Mycobacterium tuberculosis. Biochemistry 47:6092\u20136102. https:\/\/doi.org\/10.1021\/bi701929m","journal-title":"Biochemistry"},{"key":"10114_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.cmi.2020.12.017","volume":"27","author":"RY Xue","year":"2021","unstructured":"Xue RY, Liu C, Xiao QT et al (2021) HtrA family proteases of bacterial pathogens: pros and cons for their therapeutic use. Clin Microbiol Infect 27:559\u2013564. https:\/\/doi.org\/10.1016\/j.cmi.2020.12.017","journal-title":"Clin Microbiol Infect"},{"key":"10114_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femsle\/fnab141","volume":"368","author":"D Radhakrishnan","year":"2021","unstructured":"Radhakrishnan D, Amrutha MC, Hutterer E et al (2021) High temperature requirement A (HtrA) protease of Listeria monocytogenes and its interaction with extracellular matrix molecules. FEMS Microbiol Lett 368:1\u201311. https:\/\/doi.org\/10.1093\/femsle\/fnab141","journal-title":"FEMS Microbiol Lett"},{"key":"10114_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/acsptsci.0c00106","volume":"3","author":"JH Shrimp","year":"2020","unstructured":"Shrimp JH, Kales SC, Sanderson PE et al (2020) An enzymatic TMPRSS2 assay for Assessment of clinical candidates and Discovery of inhibitors as potential treatment of COVID-19. ACS Pharmacol Transl Sci 3:997\u20131007. https:\/\/doi.org\/10.1021\/acsptsci.0c00106","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10114_CR12","doi-asserted-by":"publisher","first-page":"e0086121","DOI":"10.1128\/jvi.00861-21","volume":"95","author":"G Sun","year":"2021","unstructured":"Sun G, Sui Y, Zhou Y et al (2021) Structural basis of covalent inhibitory mechanism of TMPRSS2-Related serine proteases by Camostat. J Virol 95:e0086121. https:\/\/doi.org\/10.1128\/jvi.00861-21","journal-title":"J Virol"},{"key":"10114_CR13","doi-asserted-by":"publisher","first-page":"e2108728118","DOI":"10.1073\/pnas.2108728118","volume":"118","author":"M Mahoney","year":"2021","unstructured":"Mahoney M, Damalanka VC, Tartell MA et al (2021) A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci U S A 118:e2108728118. https:\/\/doi.org\/10.1073\/pnas.2108728118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10114_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0141169","volume":"10","author":"S Nimishakavi","year":"2015","unstructured":"Nimishakavi S, Raymond WW, Gruenert DC, Caughey GH (2015) Divergent inhibitor susceptibility among airway lumen-accessible tryptic proteases. PLoS ONE 10:1\u201317. https:\/\/doi.org\/10.1371\/journal.pone.0141169","journal-title":"PLoS ONE"},{"key":"10114_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Vedantham P, Lu K et al (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116:76\u201384. https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.011","journal-title":"Antiviral Res"},{"key":"10114_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pupt.2015.07.001","volume":"33","author":"M Yamaya","year":"2015","unstructured":"Yamaya M, Shimotai Y, Hatachi Y et al (2015) The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. Pulm Pharmacol Ther 33:66\u201374. https:\/\/doi.org\/10.1016\/j.pupt.2015.07.001","journal-title":"Pulm Pharmacol Ther"},{"key":"10114_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/JPET.120.000219","volume":"375","author":"W Sun","year":"2020","unstructured":"Sun W, Zhang X, Cummings MD et al (2020) Targeting enteropeptidase with reversible covalent inhibitors to achieve metabolic benefits. J Pharmacol Exp Ther 375:510\u2013521. https:\/\/doi.org\/10.1124\/JPET.120.000219","journal-title":"J Pharmacol Exp Ther"},{"key":"10114_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.intimp.2017.10.016","volume":"54","author":"S Homma","year":"2018","unstructured":"Homma S, Hayashi K, Yoshida K et al (2018) Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Int Immunopharmacol 54:39\u201345. https:\/\/doi.org\/10.1016\/j.intimp.2017.10.016","journal-title":"Int Immunopharmacol"},{"key":"10114_CR19","doi-asserted-by":"publisher","first-page":"105325","DOI":"10.1016\/j.antiviral.2022.105325","volume":"202","author":"Y Yan","year":"2022","unstructured":"Yan Y, Yang J, Xiao D et al (2022) Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. Antiviral Res 202:105325. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105325","journal-title":"Antiviral Res"},{"key":"10114_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1254\/jphs.92.420","volume":"92","author":"S Mori","year":"2003","unstructured":"Mori S, Itoh Y, Shinohata R et al (2003) Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 92:420\u2013423. https:\/\/doi.org\/10.1254\/jphs.92.420","journal-title":"J Pharmacol Sci"},{"key":"10114_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H et al (2020) Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 64:1\u20137. https:\/\/doi.org\/10.1128\/AAC.00754-20","journal-title":"Antimicrob Agents Chemother"},{"key":"10114_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ijid.2020.05.072","volume":"96","author":"S Jang","year":"2020","unstructured":"Jang S, Rhee JY (2020) Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis 96:500\u2013502. https:\/\/doi.org\/10.1016\/j.ijid.2020.05.072","journal-title":"Int J Infect Dis"},{"key":"10114_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5090\/kjtcs.2018.51.2.114","volume":"51","author":"SJ Han","year":"2018","unstructured":"Han SJ, Han W, Song HJ et al (2018) Validation of nafamostat mesilate as an anticoagulant in extracorporeal membrane oxygenation: a large-animal experiment. Korean J Thorac Cardiovasc Surg 51:114\u2013121. https:\/\/doi.org\/10.5090\/kjtcs.2018.51.2.114","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"10114_CR24","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-04-0084","volume":"10","author":"WH Yoon","year":"2004","unstructured":"Yoon WH, Jung YJ, Kim TD et al (2004) Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res 10:4517\u20134526. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0084","journal-title":"Clin Cancer Res"},{"key":"10114_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/jpet.102.041988","volume":"305","author":"M Yuksel","year":"2003","unstructured":"Yuksel M, Okajima K, Uchiba M, Okabe H (2003) Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-\u03b1 production by inhibiting activation of both nuclear factor-\u03baB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 305:298\u2013305. https:\/\/doi.org\/10.1124\/jpet.102.041988","journal-title":"J Pharmacol Exp Ther"},{"key":"10114_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5009\/gnl.2009.3.3.205","volume":"3","author":"HC Jae","year":"2009","unstructured":"Jae HC, In SL, Hyung KK et al (2009) Nafamostat for prophylaxis against post-endoscopic retrograde cholangiopancreatography pancreatitis compared with gabexate. Gut Liver 3:205\u2013210. https:\/\/doi.org\/10.5009\/gnl.2009.3.3.205","journal-title":"Gut Liver"},{"key":"10114_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7","volume":"1263","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan S, Olson A (2015) Small- molecule Library Screening by docking with PyRx. Methods Mol Biol 1263:243\u2013250. https:\/\/doi.org\/10.1007\/978-1-4939-2269-7","journal-title":"Methods Mol Biol"},{"key":"10114_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/pro.118","volume":"18","author":"G Spraggon","year":"2009","unstructured":"Spraggon G, Hornsby M, Shipway A et al (2009) Active site conformational changes of prostasin provide a new mechanism of protease regulation by divalent cations. Protein Sci 18:1081\u20131094. https:\/\/doi.org\/10.1002\/pro.118","journal-title":"Protein Sci"},{"key":"10114_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1097-2765(04)00160-1","volume":"14","author":"K Ponnuraj","year":"2004","unstructured":"Ponnuraj K, Xu Y, MacOn K et al (2004) Structural analysis of engineered bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell 14:17\u201328. https:\/\/doi.org\/10.1016\/S1097-2765(04)00160-1","journal-title":"Mol Cell"},{"key":"10114_CR30","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1016\/j.bpj.2022.08.034","volume":"18","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Wu J, Xue G et al (2022) Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat. Biophys J 18:3940\u20133949. https:\/\/doi.org\/10.1016\/j.bpj.2022.08.034","journal-title":"Biophys J"},{"key":"10114_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41589-022-01059-7","volume":"18","author":"BJ Fraser","year":"2022","unstructured":"Fraser BJ, Beldar S, Seitova A et al (2022) Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation. Nat Chem Biol 18:963\u2013971. https:\/\/doi.org\/10.1038\/s41589-022-01059-7","journal-title":"Nat Chem Biol"},{"key":"10114_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-017-0162-533","volume":"15","author":"S Wessler","year":"2017","unstructured":"Wessler S, Schneider G, Backert S (2017) Bacterial serine protease HtrA as a promising new target for antimicrobial therapy? Cell Commun Signal 15:1\u20135. https:\/\/doi.org\/10.1186\/s12964-017-0162-533","journal-title":"Cell Commun Signal"},{"key":"10114_CR33","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1016\/j.bmc.2009.01.073","volume":"17","author":"P Hauske","year":"2009","unstructured":"Hauske P, Meltzer M, Ottmann C et al (2009) Selectivity profiling of DegP substrates and inhibitors. Bioorg Med Chem 17:2920\u20132924. https:\/\/doi.org\/10.1016\/j.bmc.2009.01.073","journal-title":"Bioorg Med Chem"},{"key":"10114_CR34","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1002\/anie.201504035","volume":"54","author":"AM Perna","year":"2015","unstructured":"Perna AM, Rodrigues T, Schmidt TP et al (2015) Fragment-based De Novo Design reveals a small-molecule inhibitor of Helicobacter Pylori HtrA. Angew Chem Int Ed Engl 54:10244\u201310248. https:\/\/doi.org\/10.1002\/anie.201504035","journal-title":"Angew Chem Int Ed Engl"},{"key":"10114_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/mmi.12306","volume":"89","author":"S Gloeckl","year":"2013","unstructured":"Gloeckl S, Ong VA, Patel P et al (2013) Identification of a serine protease inhibitor which causes inclusion vacuole reduction and is lethal to Chlamydia trachomatis. Mol Microbiol 89:676\u2013689. https:\/\/doi.org\/10.1111\/mmi.12306","journal-title":"Mol Microbiol"},{"key":"10114_CR36","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1016\/j.bmc.2019.07.049","volume":"27","author":"AA Agbowuro","year":"2019","unstructured":"Agbowuro AA, Hwang J, Peel E et al (2019) Structure-activity analysis of peptidic Chlamydia HtrA inhibitors. Bioorg Med Chem 27:4185\u20134199. https:\/\/doi.org\/10.1016\/j.bmc.2019.07.049","journal-title":"Bioorg Med Chem"},{"key":"10114_CR37","doi-asserted-by":"publisher","first-page":"113692","DOI":"10.1016\/j.ejmech.2021.113692","volume":"224","author":"J Hwang","year":"2021","unstructured":"Hwang J, Strange N, Phillips MJA et al (2021) Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues. Eur J Med Chem 224:113692. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113692","journal-title":"Eur J Med Chem"},{"key":"10114_CR38","doi-asserted-by":"publisher","first-page":"114064","DOI":"10.1016\/j.ejmech.2021.114064","volume":"230","author":"J Hwang","year":"2022","unstructured":"Hwang J, Strange N, Mazraani R et al (2022) Design, synthesis and biological evaluation of P2-modified proline analogues targeting the HtrA serine protease in Chlamydia. Eur J Med Chem 230:114064. https:\/\/doi.org\/10.1016\/j.ejmech.2021.114064","journal-title":"Eur J Med Chem"},{"key":"10114_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.csbj.2020.12.035","volume":"19","author":"H Zhu","year":"2021","unstructured":"Zhu H, Du W, Song M et al (2021) Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2. Comput Struct Biotechnol J 19:467\u2013476. https:\/\/doi.org\/10.1016\/j.csbj.2020.12.035","journal-title":"Comput Struct Biotechnol J"},{"key":"10114_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-67578-2","volume":"10","author":"S Bernegger","year":"2020","unstructured":"Bernegger S, Brunner C, Vizovi\u0161ek M et al (2020) A novel FRET peptide assay reveals efficient Helicobacter pylori HtrA inhibition through zinc and copper binding. Sci Rep 10:1\u201313. https:\/\/doi.org\/10.1038\/s41598-020-67578-2","journal-title":"Sci Rep"}],"container-title":["The Protein Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-023-10114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10930-023-10114-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-023-10114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:38:42Z","timestamp":1744213122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10930-023-10114-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10114"],"URL":"https:\/\/doi.org\/10.1007\/s10930-023-10114-8","relation":{},"ISSN":["1572-3887","1875-8355"],"issn-type":[{"value":"1572-3887","type":"print"},{"value":"1875-8355","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"12 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}